Veru (NASDAQ:VERU) Posts Earnings Results, Beats Expectations By $0.01 EPS

Veru (NASDAQ:VERU) posted its earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01, Zacks reports. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%.

Veru Stock Performance

Shares of NASDAQ:VERU opened at $0.71 on Wednesday. Veru has a one year low of $0.36 and a one year high of $1.92. The stock has a market capitalization of $104.42 million, a price-to-earnings ratio of -1.49 and a beta of -0.50. The company has a 50-day simple moving average of $0.75 and a 200-day simple moving average of $0.82.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer reiterated an “outperform” rating and issued a $5.00 price objective on shares of Veru in a research note on Tuesday, November 5th.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.